While the rest of us worry about rising hospital bills, KIMS is busy building hospitals like they’re multiplexes in Tier-2 cities. From Thane to Bangalore, every quarter seems like an IPL auction of new beds. But revenue jumped 27% YoY—proving that sickness sells. Unfortunately, margins caught a mild flu, down from 26.6% to 22.7%. Stick around: this call had everything—new units bleeding, mature clusters squeezing, and insurance empanelments moving slower than government paperwork.
2. At a Glance
Revenue ₹879 cr (+27% YoY, +10% QoQ) – Patients checked in, so did cash.
EBITDA ₹200 cr (+9% YoY, -1% QoQ) – Healthy on paper, but new units gave it a fever.
PAT ₹85 cr (-11% YoY, -20% QoQ) – Profit went on IV support.
EPS ₹1.96 (-9% YoY) – Flatlining compared to FY25 highs.
Net Debt ₹2,020 cr – Debt rising like BP after hearing hospital bills.
New Units Losses ₹21 cr – Maharashtra & Kerala took the blame.
Bed Capacity 8,000+ (25 centers) – Because growth = more beds, always.
3. Management’s Key Commentary
Dr. Bhaskar Rao: “It’s our silver jubilee; we started with one hospital in Nellore, now 25 centers.” (Translation: From hometown clinic to corporate hospital chain, and patients still can’t find parking.)
On new units: “Thane ramp-up better than expected, Nashik delayed due to insurance.” (Translation: One hospital’s on steroids, the other stuck in paperwork ICU.)
On Kerala: “Kannur EBITDA positive, Kollam dragged due to renovation.” (Translation: Fancy interiors > profits, at least for now.)
Abhinay Bollineni: “Bangalore 800 beds to breakeven in 12 months.” (Translation: Optimism prescription filled; reality check due in FY27.)
On Telangana: “Mature cluster, 5–6% volume growth, adding new capacity soon.” (Translation: Old cash cow still grazing, but grass running out.)
CFO Sachin Salvi: “Net debt at ₹2,020 cr.” (Translation: We expanded hospitals, but also our loan book.)
4. Numbers Decoded
Metric
Value (Q1 FY26)
YoY Change
One-Line Analysis
Revenue – The Hero
₹879 cr
+26.8%
Topline pumped by new hospitals opening doors.
EBITDA – The Sidekick
₹200 cr
+8.5%
Growth slowed, weighed by losses in newbies.
EBITDA Margin – Diva
22.7%
-390 bps
Margin shrank faster than hospital gowns.
PAT – The Survivor
₹85 cr
-10.5%
Profit under pressure from higher costs.
EPS – The Token
₹1.96
-9.2%
Shareholders need patience, not prescriptions.
New Units Losses
₹21 cr
N/A
Thane, Nashik, Kollam – the ICU ward of P&L.
Net Debt – The Burden
₹2,020 cr
Higher
Debt expansion matches bed expansion.
ARPOB – The Pulse
₹43,000
+11-12%
Pricing power intact, especially in mature clusters.
